RecruitingPhase 2NCT07108309

BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer

A Randomized, Open-label, Comparative Clinical Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer

Sponsor

Biocad

Enrollment

124 participants

Start Date

Jul 15, 2024

Study Type

INTERVENTIONAL

Summary

To study the efficacy, safety, pharmacokinetics and immunogenicity of BCD-236 in combination with chemotherapeutic agents (CHT) in 2nd and subsequent lines of therapy of subjects with relapsed and/or metastatic triple negative breast cancer (TNBC).

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 74 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a drug called BCD-236 — which targets a protein called AXL — in combination with chemotherapy for women with relapsed or metastatic triple-negative breast cancer (TNBC). TNBC is an aggressive form of breast cancer that lacks the three most common receptors, making it harder to treat with targeted therapies. **You may be eligible if:** - You are between 18 and 75 years old - You have been diagnosed with triple-negative breast cancer (confirmed by biopsy) - Your cancer has come back or is progressing after at least one prior treatment - Your cancer cells express the AXL protein - You experienced relapse within 6 months of completing adjuvant chemotherapy, or your cancer progressed during metastatic treatment **You may NOT be eligible if:** - Your cancer is not triple-negative - Your cancer cells do not express AXL - You have not had any prior treatment - You have significant organ problems or other serious health conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBCD-236

as an intravenous infusion

DRUGChemotherapy

CHT (at the investigator's discretion):

Locations(47)

Health Institution "Brest Regional Oncology Center"

Brest, Belarus

"Gomel Regional Clinical Oncology Dispensary"

Homyel, Belarus

Minsk City Oncology Center

Minsk, Belarus

State Budgetary Institution of Healthcare of the Arkhangelsk Region "Arkhangelsk Clinical Oncology Dispensary"

Arkhangelsk, Russia

Regional State Budgetary Healthcare Institution "Altai Regional Oncology Dispensary"

Barnaul, Russia

SBHI "Chelyabinsk regional clinical center Oncology and nuclear medicines"

Chelyabinsk, Russia

Budgetary healthcare institution of the Udmurt Republic "Republican clinical oncology dispensary named after Sergei Grigorievich Primushko of the Ministry of Health of the Udmurt Republic

Izhevsk, Russia

SBHI of the Kaluga Region "Kaluga Regional Clinical Oncology Center"

Kaluga, Russia

State Autonomous Institution of Health "Republican Clinical Oncological Dispensary of the Ministry of Health of the Republic of Tatarstan named after prof. M.Z.Sigal"

Kazan', Russia

SBHI "Clinical oncological Dispensary № 1" of the Ministry of Health of the Krasnodar Territory

Krasnodar, Russia

Branch of company "Hadassah Medical LCC"

Moscow, Russia

Federal State Budgetary Scientific Institution "Russian Scientific Center of Surgery named after Academician B.V. Petrovsky"

Moscow, Russia

FSAEI of Higher Education "First Moscow State Medical University named after I.M. Sechenov" of the Ministry of Health of the Russian Federation

Moscow, Russia

FSAEI of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Moscow, Russia

FSAI "National Medical Research Center for Therapeutic and Rehabilitation Center" of the Ministry of Health of the Russian Federation

Moscow, Russia

FSBI "Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency"

Moscow, Russia

FSBI "National Medical Research Center of Oncology named after N. N. Blokhin" of the Ministry of Health of the Russian Federation

Moscow, Russia

Joint Stock Company "Medsi Group of Companies"

Moscow, Russia

JSC "Modern medical technologies"

Moscow, Russia

Limited Liability Company "Moscow Center for Rehabilitation Treatment"

Moscow, Russia

SBHI of the City of Moscow "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of the Moscow City Health Department"

Moscow, Russia

State Budgetary Institution of Healthcare of the City of Moscow "City Clinical Hospital named after S.S. Yudin of the Moscow City Health Department

Moscow, Russia

State Budgetary Institution of Healthcare of the City of Moscow "Moscow City Oncology Hospital No. 62 of the Moscow City Healthcare Department"

Moscow, Russia

SAHI of the Nizhny Novgorod region "Research Institute of Clinical Oncology "Nizhny Novgorod Regional Clinical Oncological Dispensary"

Nizhny Novgorod, Russia

FBHI of the Novosibirsk Region "Novosibirsk Regional Clinical Oncological Dispensary"

Novosibirsk, Russia

FSBI "National Medical Research Center for Radiology" of the Ministry of Health of the Russian Federation

Obninsk, Russia

FSBI "National Medical Research Center of Radiology" of the Ministry of Health of the Russian Federation Medical Radiological Research Center named after A.F. Tsyb

Obninsk, Russia

Budget Healthcare Institution of the Omsk region "Clinical Oncological Dispensary"

Omsk, Russia

FSBI "National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation

Rostov-on-Don, Russia

State budgetary institution of the Ryazan region "Regional clinical oncology dispensary"

Ryazan, Russia

FSBEI of Higher Education "North-Western State Medical University named after I. I. Mechnikov" of the Ministry of Health of the Russian Federation

Saint Petersburg, Russia

FSBI "National medical research center of Oncology named after N.N. Petrov" Of Ministry of Health of the Russian Federation, Department of Breast Cancer Surgery

Saint Petersburg, Russia

FSBI "National medical research center of Oncology named after N.N. Petrov" Of Ministry of Health of the Russian Federation, Research Division of Innovative Techniques in Medical Oncology and Rehabilitation Medicine

Saint Petersburg, Russia

LLC "NRC Eco-Safety"

Saint Petersburg, Russia

LLC "VitaMed"

Saint Petersburg, Russia

Private healthcare institution "Clinical hospital "RZD-Medicine" of the city of St. Petersburg"

Saint Petersburg, Russia

Private medical institution "Euromedservice"

Saint Petersburg, Russia

SBHI "St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named after N.P. Napalkov"

Saint Petersburg, Russia

SBHI of St. Petersburg "City Clinical Oncology Dispensary"

Saint Petersburg, Russia

State Budgetary Healthcare Institution Leningrad Regional Clinical Hospital

Saint Petersburg, Russia

Federal State Budgetary Educational Institution of Higher Education "National Research Mordovian State University named after N.P. Ogarev"

Saransk, Russia

SBHI Arkhangelsk Region "Severodvinsk City Clinical Hospital No. 2 for Emergency Medicine"

Severodvinsk, Russia

State Budgetary Healthcare Institution "Tambov Regional Oncology Clinical Dispensary"

Tambov, Russia

SAHI Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Bashkortostan

Ufa, Russia

SBHI "Volgograd Regional Clinical Oncological Dispensary"

Volgograd, Russia

SBHI of the Yaroslavl region "Regional Clinical Oncological Hospital"

Yaroslavl, Russia

SAHI of the Sverdlovsk region "Sverdlovsk Regional Oncological Center"

Yekaterinburg, Russia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07108309